@article{10902/29839,
year = {2023},
url = {https://hdl.handle.net/10902/29839},
abstract = {Adipose tissue malfunction leads to altered adipokine secretion which might consequently contribute to an array of metabolic diseases spectrum including obesity, diabetes mellitus, and cardiovascular disorders. Asprosin is a novel diabetogenic adipokine classified as a caudamin hormone protein. This adipokine is released from white adipose tissue during fasting and elicits glucogenic and orexigenic effects. Although white adipose tissue is the dominant source for this multitask adipokine, other tissues also may produce asprosin such as salivary glands, pancreatic B-cells, and cartilage. Significantly, plasma asprosin levels link to glucose metabolism, lipid profile, insulin resistance (IR), and b-cell function. Indeed, asprosin exhibits a potent role in
the metabolic process, induces hepatic glucose production, and influences appetite behavior. Clinical and preclinical research showed dysregulated levels of circulating asprosin in several metabolic diseases including obesity, type 2 diabetes mellitus (T2DM), polycystic ovarian syndrome (PCOS), non-alcoholic fatty liver (NAFLD), and several types of cancer. This review provides a comprehensive overview of the asprosin role in the etiology and pathophysiological manifestations of these conditions. Asprosin could be a promising candidate for both novel pharmacological treatment strategies and diagnostic tools, although developing a better understanding of its function and signaling pathways is still needed.},
organization = {Funding: OG and FL are Staff Personnel (I3SNS Stable Researcher) of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff contract (ISCIII)/SERGAS). OG and MG-G are members of RICORS Program, RD21/0002/0025 via ISCIII and FEDER. FL is a member of Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV). The work of OG and JP (PI20/00902), and FL (PI21/01145 and CB16/11/00226) is funded by ISCIII and FEDER. OG is a beneficiary of a project funded by the Research Executive Agency of the European Union in the framework of MSCARISE Action of the H2020 Program (project number 734899). OG is the beneficiary of a grant funded by Xunta de Galicia, Consellerı́a de Educación, Universidade e Formación Profesional and Consellerı́a de Economı́a, Emprego e Industria (GAIN) (GPC IN607B2022/03). MG-R is a recipient of a predoctoral contract funded by Xunta de Galicia (IN606A-2020/010). ISCIII and FEDER funded through a predoctoral research scholar to CR-F (Exp.18/00188). AC-B is a recipient of a predoctoral contract funded by Secretarı́a de Estado de Universidades, Investigación, Desarrollo e Innovación, Ministerio de Universidades (FPU2018- 04165). YF is a ‘Sara Borrell’ researcher funded by ISCIII and FEDER [CD21/00042].},
publisher = {Frontiers Media S.A.},
publisher = {Frontiers in endocrinology, 2023, 13, 1101091},
title = {Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects},
author = {Farrag, Mariam and Ait Eldjoudi, Djedjiga and González-Rodríguez, María and Cordero-Barreal, Alfonso and Ruiz-Fernández, Clara and Capuozzo, Maurizio and González-Gay Mantecón, Miguel Ángel and Mera, Antonio and Lago, Francisca and Soffar, Ahmed and Essawy, Amina and Pino, Jesus and Farrag, Yousof and Gualillo, Oreste},
}